Viva Star Biosciences (Suzhou) Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
Researchers from Kanaph Therapeutics Inc. and Korea Research Institute of Chemical Technology have disclosed prostanoid EP2 and/or EP4 receptor subtype dual antagonists reported to be useful for the treatment of cancer.
Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated several Masimo patents for physiological monitoring. However, the two companies are not finished with each other yet as the International Trade Commission has yet to rule on a similar case that could foreclose importation of Apple devices on grounds of patent infringement.
Medwatch Technologies Inc. reported a patent for the use of near infrared (NIR) spectroscopy, from collection of NIR LEDs surrounding a photo diode sensitive to wavelengths in the range 400 nm to 1650 nm, to noninvasively detect blood glucose concentrations, in a multi-sensing wearable device such as a watch or patch.
Researchers at Ontario Institute for Cancer Research and Sunnybrook Research Institute have described isoquinoline derivatives acting as apoptosis regulator BAX and/or BAK inhibitors reported to be useful for the treatment of neurodegenerative disorders.
Insusense ApS has identified sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, glaucoma, hearing loss and cardiovascular disorders, among others.
Inversago Pharma Inc. has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome.
Cancer Research Technology Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bonded to a mitogen-activated protein kinase 7 (MAPK7; ERK5)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Shanghai SIMR Biotech Co. Ltd. has developed imidazopyridazine derivatives acting as GABA-A modulators and reported to be useful for the treatment of pain, Alzheimer’s disease, multi-infarct dementia, epilepsy, pruritus and stroke.
RSS
